InTroduCTIon
Undiagnosed HIV infections could potentially undermine efforts to reverse the AIDS pandemic within the next two decades. 1 These efforts rely on the early initiation of combination antiretroviral therapy (ART), which can prevent the transmission of HIV between infected persons and their uninfected partners. [2] [3] [4] [5] For this reason, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has set an ambitious target to reduce the undiagnosed population size to the 10% level (or below) by the year 2020. 6 While some mathematical models predict this target can be reached, 7 real-world data are needed to evaluate progress. Such data could also be used to reveal the limitations of existing HIV testing strategies and inform the future need for ART. [8] [9] [10] Population-based surveillance systems are a good source of data for estimating the number of undiagnosed HIV cases. These estimates can be derived from a back-calculation approach that uses the number of HIV/AIDS diagnoses recorded for each year of the surveillance period. 11 However, several variants of this approach require additional data to improve inference about the distribution of time from infection to diagnosis. For example, the London, 12 Cambridge, 13 Atlanta, 14 Ottawa/ Sydney 15 and Paris 16 methods use either routinely collected CD4+ T cell count data, the clinical status of the patient at diagnosis, or the diagnosis of a prior seroconversion illness. But such clinical and/ or laboratory data may be too costly to obtain in most sub-Saharan African settings, even if population-based surveillance systems are currently in place.
The Seattle 17 method is a promising variant that uses data from only the latest HIV-negative and earliest HIV-positive test results. This method is therefore well suited for surveillance systems in which participants are repeatedly tested for HIV. In the case of missing data, a straightforward procedure can be used to impute the HIV-negative test date. The Seattle method also back-calculates the incidence of HIV infection and then derives the number of undiagnosed cases from this result. Using the Seattle method and data from a population-based surveillance system, we estimated the percentage of undiagnosed HIV cases in a hyperendemic South African community between 2005 and 2016.
MeThods surveillance system
The Africa Health Research Institute (AHRI) maintains a population-based surveillance system in the Umkhanyakude district of the KwaZulu-Natal province. The surveillance area is 438 km² in size with a population of approximately 90 000 people. 18 Most of the surveillance area is poor and rural, with several informal periurban settlements and a single urban township. Households tend to be scattered across the landscape. Annual HIV testing has been ongoing since January 2004. Trained fieldworkers visit households every 12 months and identify eligible participants older than 15 years for HIV testing. After obtaining consent, the fieldworkers then extract blood according to the UNAIDS and WHO Guidelines for Using HIV Testing Technologies in Surveillance.
Previous work has shown a high burden of HIV in the surveillance area. Between 2004 and 2014, the overall HIV incidence was 3.7 new infections per 100 personyears (95% CI 3.6 to 3.9). 19 By sex and age group, incidence was highest in women aged [20] [21] [22] [23] [24] 20 21 ART was made available to patients with CD4+ T cell counts <200 cells/ µL through public sector healthcare clinics in 2004 and then to all adult patients in 2011. 22 
seattle method
The Seattle 17 method relies on the participant's latest HIV-negative and earliest HIV-positive test dates. Using these data, the method estimates the population distribution of time from infection to HIV diagnosis (TID). Thereafter, the TID is used to calculate the annual number of undiagnosed HIV cases. In our study, 9510 (79%) of the 12 039 HIV-positive participants did not have an HIV-negative test date. We therefore had to impute a latest HIV-negative test date for these participants.
Imputation of the latest hIV-negative date
The imputation procedure for the latest HIV-negative test date is based on the Seattle method. Using the following notation, let i denote the i th HIV-positive participant for i = 1, . . . , n, where n=12 039. Let l i be the latest HIV-negative test date and r i be the earliest HIV-positive test date, and let x i = r i − l i , which we call the censored interval. Further, let s= 1 January 2005 be the start of the observation period and the date at which undiagnosed time begins to accumulate.
We first defined a maximum censored interval length for all participants with a missing HIV-negative test date. To do this, we used the result of Morgan et al, 23 who showed that the time from infection to AIDS was approximately 10 years for 75% of persons living in a rural sub-Saharan African setting. We therefore subtracted 10 years from the earliest HIV-positive test date (r i ) to obtain the imputed HIV-negative test date (l i ), with two exceptions to this rule. First, if this '10 year' imputed HIV-negative date came before the start date (s), then we made it equal to the start date (ie l i = s if l i < s). For example, if a 30-year-old participant had an earliest HIV-positive test date on 1 July 2013, then we imputed the HIV-negative date on 1 January 2005. As a sensitivity analysis, we also evaluated 11, 12 and 13-year periods from infection to AIDS. Second, if the imputed HIV-negative date came before the participant's 16th birthdate (b i ), then we made it equal to the 16th birthdate
We use the 16th birthdate to represent the age of first sex and the earliest possible date of HIV infection. This second assumption therefore excludes earlier HIV infection events that could have been acquired vertically or through other transmission routes. As a sensitivity analysis, we also evaluated a 15th birthdate of sexual debut (but could not go lower than this birthdate given our ≥15-year age eligibility criteria for HIV testing).
Since some participants could potentially have three different imputed dates, we selected the minimum censored interval length for each participant, that is,
. For these 9510 participants, we imputed a latest HIV-negative date at the start date for 7171 (75%) participants, at the 16th birthdate for 1228 (13%) participants and at a 10-year date prior to their earliest HIV-positive test date for 1111 (12%) participants.
estimating the TId
The Seattle method uses the i th participant's censored interval to estimate the population distribution of the TID. Because the exact infection date is rarely observed during periodic testing, the method performs a sensitivity analysis using two different assumptions: (1) the base case (BC), which places an equal probability of infection on every time point within the censored interval; and (2) the upper bound (UB), which assumes that the infection date occurs 1 day after the latest HIV-negative test date. A lower bound assumption is not evaluated here because, from an HIV treatment-as-prevention (TasP) perspective, we are interested in the worst-case scenario, which is the maximum possible number of undiagnosed cases.
Following the notation of Fellows et al, 17 let the cumulative hazard of diagnosis be defined as
and the survival function of the remaining diagnoses
is evaluated under the UB assumption as:
where I is an indicator function (
is the empirical cumulative density function of the TID. We note that the UB assumption represents the maximum amount of time that an infected participant can remain undiagnosed. It does not reflect a reason or motivation for the participant to test at any one point in time, as this is determined by the annual testing schedule of the AHRI surveillance system. Under the BC assumption, F(t) is evaluated as:
Equation (2) shows that the BC assumption does not impute a random infection event within the censored interval. Rather, the cumulative probability of infection within the censored interval is 100%-and this probability has a uniform distribution. The discretised TID density is then obtained for the BC and UB assumptions for each year of the observation period, given
, which is the probability that a participant is diagnosed t years after infection.
Calculation of the undiagnosed hIV cases
The Seattle method then uses a Poisson process with rate λ i to back-calculate the yearly HIV incidence. 17 Once the incidence rate is obtained, the number of undiagnosed cases can be estimated with:
For this calculation, each term in the outer sum represents the expected number infected during year t who are diagnosed after year t plus half the expected number of cases diagnosed during year t. To calculate the undiagnosed percentage, we divided the
, by the total number of HIV-positive participants in our surveillance area for year t under the BC and UB assumptions. For visualisation purposes, we fitted a kernel smoother to the estimates. We performed all analyses in R software V.3.4.0 using the HIVBackCalc package. figure 1 .
As a sensitivity analysis, we also evaluated 11, 12 and 13-year periods from infection to AIDS. Results show that longer periods increased the average censored interval length, which consequently increased the number of undiagnosed HIV cases. Using 2016 data as an example, the BC estimate under the 10-year infection period rose from 18.86% (UB=37.6%) to 19.20% (UB=39.35%) under the 11-year period, and then to 21.88% (UB=46.19%) under the 12-year period, as shown in online supplementary table S1. Online supplementary table S2 shows the results for the 15th birthdate assumption under the three infection periods. Lowering the birthdate also increased the average length of the censored interval, leading to a slight increase in the percentage of undiagnosed HIV cases. The estimates we report in table 2, which use a 10-year infection period and a 16th birthdate, can therefore be considered as conservative, since longer infection periods and a lower birthdate lead to a higher percentage of undiagnosed cases within the surveillance area.
dIsCussIon
We have estimated the percentage of undiagnosed cases within a hyperendemic South African community, using data from one of the world's largest HIV surveillance programmes. Our results show that the percentage of undiagnosed cases declined from 29.3% (UB=47.1%) in 2005 to 15.8% (UB=32.8%) in 2011, but then steadily increased back to 18.9% (UB=37.6%) in 2016. This 2016 estimate is far from the UNAIDS target to reduce the *Because the exact infection date is rarely observed during periodic testing, the Seattle method calculates the undiagnosed percentage using two assumptions: (1) the base case (BC), which places an equal probability of infection on every time point between the latest HIV-negative and earliest HIV-positive test dates; and (2) the upper bound (UB), which assumes that the infection event occurs 1 day after the latest HIV-negative test date.
undiagnosed population size to the 10% level (or below) by the year 2020. The increase in the percentage of undiagnosed HIV cases between 2012 and 2016 is due to the high percentage of participants who refused to test or who missed their scheduled test dates. Refusal rates peaked at 70% in 2008 and then declined to 41.3% in 2016, which is an alarmingly high percentage. By the end of 2016, approximately 25% of all participants in our surveillance area had still not tested for HIV, despite ongoing annual testing since 2005. Overall, only 20% of the participants in our surveillance area continually consent to testing, whereas 37% refuse to test and 43% switch between consent and refusal. 24 The low HIV testing rate is likely due to a range of social and behavioural factors associated with testing fatigue, 24 poverty and inequality, 25 social disequilibrium, 26 stigma 27 and frequent cyclical migration 28 within the AHRI surveillance area. The low testing rate can explain, in large part, the high percentage of undiagnosed cases over the last 5 years of the observation period. As previous research has shown, missed test dates will lengthen the time between the latest HIV-negative and earliest HIV-positive test dates, 29 otherwise known as the censored interval. In our surveillance cohort, the average censored interval length increased from 1.1 years in 2005 to 4.3 years in 2016. Thus, the early decline in the percentage of undiagnosed cases over the 2005-2011 period was likely offset by an increase in the amount of undiagnosed time, which led to a greater percentage of undiagnosed cases from 2012 onwards.
One possible limitation of this study is that a substantial percentage (79%) of the 12 039 participants did not have an HIV-negative test result, which is a common problem for large HIV surveillance systems. We therefore had to infer a latest HIV-negative date for these participants: either 10 years prior to the earliest HIV-positive test date, at the start of the study period, or at the 16th birthdate-whichever gave the shortest censored interval. By selecting the shortest interval, it is likely that we reduced the average amount of undiagnosed time, and therefore underestimated the percentage of undiagnosed HIV cases. Our results should therefore be considered as conservative, as demonstrated by our sensitivity analyses using 11, 12 and 13-year periods prior to the earliest HIV-positive test date.
Our analyses assumed that the HIV infection event occurred no earlier than the participant's 16th birthdate-the age of sexual debut. Although the heterosexual transmission of HIV is the predominant route of infection in sub-Saharan Africa, 30 a small but unknown proportion of participants in our study area could have acquired HIV vertically (or via other transmission routes) before their 16th birthdate. Nevertheless, the aim of this study was to quantify the percentage of undiagnosed HIV cases using data from sexually active participants, since TasP efforts are currently focused on preventing the onward transmission of HIV between serodiscordant partners. 6 Further, our sensitivity analysis showed that lowering the age of sexual debut by 1 year only increased the percentage of undiagnosed HIV cases, thus confirming the main conclusion of this study. Under the 16th birthdate assumption, our estimates can therefore be considered as conservative.
We also made the additional assumption that the number of undiagnosed cases could be reliably derived from a back-calculated HIV incidence rate. Lodwick et al 11 provide a more detailed discussion of this assumption elsewhere. Nevertheless, our estimates correspond closely with the Agence Nationale de Recherche sur le Sida (ANRS) TasP trial, which was undertaken in 22 communities adjacent to our surveillance area between March 2012 and April 2016. 31 Investigators report that between 15% and 26% of the 14 916 participants did not receive an HIV diagnosis, a range which includes our 16%-21% estimates over the 2005-2016 observation period. Results from both of these studies, which use real-world data, are higher than the 10% undiagnosed size for 2016, as projected by a previously published simulation model. 7 We show in a hyperendemic South African setting that the HIV testing rate is low, with long infection times, and an unsatisfactorily high percentage of undiagnosed cases. This scenario is problematic from a public health perspective: undiagnosed and untreated individuals will remain infectious for longer periods and have a higher probability of transmitting HIV to their uninfected sexual partners. 32 33 A high level of HIV testing is needed to minimise the time to diagnosis and reduce the number of undiagnosed cases if the global AIDS epidemic is to be reversed by 2030.
What is already known on this subject
Current treatment-as-prevention strategies aim to reduce the size of the undiagnosed HIV population to the 10% level (or below) by the year 2020. Some mathematical models predict this target can be reached; however, real-world data are critically needed to evaluate progress.
What this study adds
Using data from a population-based surveillance system, we calculated the percentage of undiagnosed HIV cases in a hyperendemic South African setting. Our results show that the percentage of undiagnosed cases was 18.9% in 2016, with an upper bound of 37.6%-much higher than the 10% target set by the Joint United Nations Programme on HIV/AIDS. A high level of repeat HIV testing is needed to minimise the time from infection to diagnosis. 
